HGH Fragment 176-191
GH fragment (lipolytic)
Also known as: hGH Frag 176-191, growth hormone fragment 176-191
Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
No pharmacokinetic half-life data exist in humans or animals. Community claims of a ~30 minute half-life have no traceable source. IDENTITY NOTE: the literature almost exclusively studies hGH 177-191 and the tyrosine-modified analog AOD-9604; the published animal work should not be assumed to transfer exactly to "176-191" as marketed.
No human dosing data for the unmodified fragment. Published work is chronic treatment in obese mice. The developed clinical candidate from this series was AOD-9604, see that entry for the only human dose data in this family. Community protocols (250-500 mcg/day) are anecdotal with no published basis.
No human safety data. The critical practical point: the optimised member of this chemical family (AOD-9604) reached Phase 2b in humans and FAILED to show commercially meaningful weight loss. There is no reason to expect the unmodified fragment to outperform it, and no human efficacy evidence exists for it at all.
- Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide · pubmed
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment · pubmed